Pregled bibliografske jedinice broj: 550287
Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase
Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase // Cephalalgia
Philadelphia (PA), Sjedinjene Američke Države: Wiley-Blackwell, 2009. str. 29-29 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 550287 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Botulinum neurotoxin type A for treatment of chronic migraine: PREEMPT 2 trial double-blind phase
Autori
Dodick, DW ; Smith, TR ; Becker, WJ ; Gendolla, A ; Relja, Maja ; Martin, V ; Reyes, C ; Lei, X ; Turkel, CC
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Cephalalgia
/ - : Wiley-Blackwell, 2009, 29-29
Skup
14th Congress of the International Headache Society
Mjesto i datum
Philadelphia (PA), Sjedinjene Američke Države, 10.09.2009. - 13.09.2009
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Chronic migraine; Botulinum toxin
Sažetak
In PREEMPT 2, BoNTA was effective as prophylaxis of headache in adults with CM. BoNTA treatment resulted in statistically and clinically meaningful improvements for all efficacy parameters evaluated, including primary endpoint (headache days). BoNTA significantly reduced headache-related disability and improved functioning and overall quality of life. Repeat BoNTA treatment was safe and well tolerated.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080003-0019 - Klinička farmakologija poremećaja pokreta (Relja, Maja, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Maja Relja
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
